Wearable Injector Enters Blood Cancer Treatment as Sarclisa U.S. Approval Reshapes the Dosing Setting
The FDA has cleared a subcutaneous version of Sanofi’s multiple myeloma drug Sarclisa. The focus is not a new target, but compressing hours-long infusion into a treatment workflow closer to the rhythm of routine outpatient care.